The acquired portfolio include CNS drug Seresta, an anti-anxiety agent used for sleep disorders and substance-withdrawal symptoms. No employees will transfer from Wyeth to Meda in conjunction with the acquisition, which is expected to inject sales of about $24-25 million into Meda’s operation for the remainder of 2007.
Meda said that the deal strengthens its position on two of its most important markets: Italy and France. These countries account for about 60% of the acquired products’ sales.